<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430754</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VEC-162-3203</org_study_id>
    <nct_id>NCT01430754</nct_id>
  </id_info>
  <brief_title>Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder</brief_title>
  <official_title>A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the maintenance effect and safety of 20 mg
      tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize
      their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their
      circadian rhythm instead reflects the intrinsic period of their endogenous circadian
      pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals
      moves gradually later and later each day if there circadian period is &gt; 24 hours and earlier
      and earlier is &lt; 24 hours. These individuals will be able to sleep well at night when their
      sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social
      cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the
      24-hour light-dark cycle will move out of synchrony with each other, and they may have
      difficulty falling asleep until well into the night. In addition to problems sleeping at the
      desired time, the subjects experience daytime sleepiness and daytime napping. As time
      progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals
      moves further and further away from the 24-hour light-dark cycle and gradually, these
      individuals are unable to sleep at night and as a result experience extreme sleepiness during
      the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake
      time moves back into alignment with the social time for sleep and the individuals sleep well
      at night and have decreased daytime napping. The alignment between their endogenous circadian
      rhythms and the 24-hour day is temporary as they are continually drifting later and later
      each day.

      This will be a multicenter, randomized withdrawal, double-masked, placebo-controlled,
      parallel study. The study has three phases: the tasimelteon run-in phase, the tau estimation
      phase, and the randomized withdrawal phase. Subjects who have participated in study
      VP-VEC-162-3201 that meet the entry criteria for this study will be eligible for the run-in
      phase The run-in phase comprises a screening visit where subject's initial eligibility will
      be evaluated. Subjects that meet the inclusion/exclusion criteria at screening will enter the
      run-in phase and will be dosed with 20 mg of tasimelteon daily for 6 weeks. The tau
      estimation phase (48 hour urine collection samples to evaluate response to tasimelteon) will
      follow the run-in phase and will last approximately 6 weeks long. The randomized withdrawal
      phase comprises approximately eight weeks of treatment with either placebo or tasimelteon 20
      mg taken approximately 1 hour prior to their target bedtime in a double-masked fashion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Run-In in Circadian Time to Relapse During the Randomized Phase</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Non-24-Hour Sleep-Wake Disorder</condition>
  <arm_group>
    <arm_group_label>tasimelteon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tasimelteon capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon</intervention_name>
    <description>20 mg tasimelteon capsules, daily</description>
    <arm_group_label>tasimelteon</arm_group_label>
    <other_name>VEC-162</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and acceptance to provide informed consent;

          2. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months
             before screening or subject is postmenopausal, without menses for 6 months before
             screening), or females of child-bearing potential using an acceptable method of birth
             control for a period of 35 days before the first dosing and must have a negative
             pregnancy test at the screening and baseline visits; Note: Women using hormonal
             methods of birth control must use an additional method of birth control during the
             study and for one month after the last dose.

          3. Willing and able to comply with study requirements and restrictions including a
             commitment to a fixed 9-hour sleep opportunity during the study;

          4. Diagnosis of N24HSWD in a previous clinical trial as measured by a tau value of &gt; 24.1
             and the lower bound of the 95% CI is &gt; 24.

        Exclusion Criteria:

          1. History (within the 12 months prior to screening) of psychiatric disorders including
             Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium
             or any other psychiatric disorder, that is not being successfully treated or has not
             been resolved and that in the opinion of the clinical investigator would affect
             participation in the study or full compliance with study procedures;

          2. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;

          3. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug
             and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption
             of alcoholic drinks (&gt; 2 drinks/day or &gt; 14 drinks/week);

             a. Note: A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol or

               -  12-ounces of beer

               -  8-ounces of malt liquor

               -  5-ounces of wine

               -  1.5-ounces or a &quot;shot&quot; of 80-proof distilled spirits or liquor (e.g., gin, rum,
                  vodka, or whiskey);

          4. Subject is at risk of suicide, in the opinion of the Investigator. Evidence of suicide
             risk could include any suicide attempt within the past year or any other suicidal
             behavior within the past year;

          5. Current clinically significant cardiovascular, respiratory, neurologic, hepatic,
             hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently
             controlled and stable;

          6. Subjects who have estimated creatinine clearance (CLcr; based on the Cockcroft-Gault
             equation) ≤ to 55 mL/min;

          7. Clinically significant deviation from normal in clinical laboratory results, vital
             signs measurements, or physical examination findings at screening as determined by the
             clinical investigator;

          8. Indication of impaired liver function (values for AST, ALT or bilirubin &gt; 2 times
             Upper Limit of Normal);

          9. Pregnant or lactating females;

         10. A positive test for drugs of abuse at the screening visit; Note: A positive drug
             screen at Visit 1 needs to be discussed with the medical monitor and will be evaluated
             on a case-by-case basis.

         11. Smoke more than 10 cigarettes/day;

         12. Worked night, rotating, or split (period of work, followed by break, and then return
             to work) shift work within 1 month of the screening visit or plan to work these shifts
             during the study;

         13. Unwilling or unable to follow the medication restrictions described in Section 8.2.,
             or unwilling or unable to sufficiently wash-out from use of a restricted medication

         14. Unable to perform calls to the study IVR system to report questionnaire results;

         15. Any other sound medical reason as determined by the clinical investigator;

         16. Legal incompetence or limited legal competence, detainment in an institution for
             official or legal reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanda Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Vanda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials Inc.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns Sleep Disorder Center - St. Johns Medical Plaza</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research Inc.</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Sleep Disorders Center - Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center Of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Lung Associates SC</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head-Pain Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine Institute (Columbus Metropolitan Area)</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma city</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Research Group Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Fitzgerald Hospital - Sleep Disorders Center (Philadelphia Metropolitan Area)</name>
      <address>
        <city>Lafayette Hill</city>
        <state>Pennsylvania</state>
        <zip>19444</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consolidated Clinical trials</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SleepMed, Inc. - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Todd J. Swick, M.D., P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <results_first_submitted>August 8, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2014</results_first_posted>
  <disposition_first_submitted>May 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2013</disposition_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blindness</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Nap Disorders</keyword>
  <keyword>Circadian Rhythm Disorders</keyword>
  <keyword>Sleep Disorders</keyword>
  <keyword>Circadian Rhythm Sleep Disorders</keyword>
  <keyword>Dyssomnias</keyword>
  <keyword>Nervous System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients who met the I/E criteria were treated with tasimelteon 20 mg for 6 wks during run-in. Entrained patients were randomized to tasimelteon 20 mg or placebo for the remainder of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tasimelteon</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-In Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="0">During the run-in phase, participants were treated with tasimelteon only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entrained - After Run-In Phase</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">Defined as the number of patients who entered the randomized-withdrawal phase</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Circadian Period Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Run-In - Not Randomized includes the demographics for patients who participated in the run-in phase but who were not randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Run-In - Not Randomized</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg capsules, daily</description>
        </group>
        <group group_id="B2">
          <title>Tasimelteon (Randomized)</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Randomized)</title>
          <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="13.18"/>
                    <measurement group_id="B2" value="51.3" spread="12.87"/>
                    <measurement group_id="B3" value="52.1" spread="12.01"/>
                    <measurement group_id="B4" value="52.1" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.</title>
        <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
        <time_frame>Approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.</title>
          <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary aMT6s collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD</title>
        <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
        <time_frame>Approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD</title>
          <description>Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (τ) was calculated using urinary cortisol collected over four separate 48 hour periods, approximately 1 week apart, during the run-in and randomized phases of the trial. Maintenance of entrainment is defined as the proportion of subjects who become non-entrained to a 24 hour day after randomization to tasimelteon or placebo. Non-entrainment was defined as having a post-baseline τ value ≥ 24.1 or the lower bound of the 95% CI &gt;24.0.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase</title>
        <description>LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.</description>
        <time_frame>Approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Run-In in Subjective Nighttime Total Sleep Time in Lower Quartile of Days (LQ-nTST) During the Randomized Phase</title>
          <description>LQ-nTST measures the average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) from run-in and randomized phase. The higher number indicates improvement.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.74" spread="18.986"/>
                    <measurement group_id="O2" value="-73.74" spread="18.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase</title>
        <description>UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.</description>
        <time_frame>Approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Run-In in Total Daytime Sleep Duration in Lower Quartile of Days (UQ-dTSD) During the Randomized Phase</title>
          <description>UQ-dTSD measures the average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) from run-in and randomized phase. Lower number indicates improvement.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.31" spread="17.253"/>
                    <measurement group_id="O2" value="49.95" spread="17.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase</title>
        <description>Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual’s sleep becomes more fragmented. Improvement is defined as an increase in the average.</description>
        <time_frame>Approximately 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Run-In in Midpoint of Sleep (MoST) During the Randomized Phase</title>
          <description>Midpoint of Sleep Timing (MoST) is the measurement of the average timing of sleep relative to bedtime. The average MoST value will trend to 0 as an individual’s sleep becomes more fragmented. Improvement is defined as an increase in the average.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.99" spread="8.611"/>
                    <measurement group_id="O2" value="-16.05" spread="8.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Run-In in Circadian Time to Relapse During the Randomized Phase</title>
        <description>Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.</description>
        <time_frame>Approximately 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tasimelteon</title>
            <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Run-In in Circadian Time to Relapse During the Randomized Phase</title>
          <description>Time to relapse is defined as a 45 minute or greater decrement in the weekly average of subjective nighttime total sleep time (nTST) compared to the Run-in Phase.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Circadian time to relapse never gets as low as 50% (median).</measurement>
                    <measurement group_id="O2" value="24.7" lower_limit="11.1" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1st dose to 30 days following last administration of study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total Run-In</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
        </group>
        <group group_id="E2">
          <title>Run-In - Not Randomized</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg capsules, daily</description>
        </group>
        <group group_id="E3">
          <title>Tasimelteon</title>
          <description>20 mg tasimelteon capsules
tasimelteon: 20 mg tasimelteon capsules, daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo capsules
Placebo: Placebo capsules, daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Serotonin Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marlene Dressman, Ph.D.</name_or_title>
      <organization>Vanda Pharmaceuticals Inc.</organization>
      <phone>202-734-3462</phone>
      <email>marlene.dressman@vandapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

